At a glance
ClinicalIndex Comparison RecordN/ACompleted· 902 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective, Observational Study to Investigate the Long-term Effect of Xalatan® on Intraocular Pressure (IOP) and on Maintenance of Visual Field in Patients With Normal Tension Glaucoma (NTG)
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·observational·Posted Sep 27, 2010·Updated Feb 26, 2021
In Brief
An observational study for Low Tension Glaucoma. Completed, enrolled 902 participants.
Detailed Summary
The purpose of this study is to assess the long-term efficacy and safety of latanoprost monotherapy in patients with normal tension glaucoma (NTG) using a prospective, observational design. Visits were scheduled at 6-month intervals for 24 months. Intraocular pressure (IOP), optic nerve head findings, visual field status, and adverse events were recorded.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsLow Tension Glaucoma
Countries--
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2006
Primary CompletionSep 2009
First PostedSep 2010
TodayJul 2026
First PostedSep 27, 2010
Enrollment StartAug 1, 2006
Primary CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 15.8 years ago